

# *Proposal Discussion Topics*

- Target Selection
  - Whom is this for? Clinical community? Basic community? Both?
  - Literature based?
  - Expression based?
  - Mass Spectrometry based?
  - Proposal based?
- Affinity Reagent platform selection
  - Are antibodies really the best?
  - Monoclonal vs. polyclonal?
  - What about other scaffolds/platforms?
  - What should we use as the determinants?
    - Experience
    - Available secondary reagents
    - Intellectual property consideration
  - Should we pick a platform or just let everyone play?
- Antigens
  - Should these be produced by each affinity reagent producer?
  - Should these be made as a centralized resource?

# *Discussion Topics II*

- Mechanisms for contracting the production of the reagents
  - Should we worry about avoiding duplicating effort?
    - OR - Duplication can be good and done at the risk of the producer
  - Should we pay only for finished antibodies?
    - Must meet established criteria
    - Validated for pre-selected applications
    - Once acquired, the target gets crossed off the list
  - Should we contract each producer in advance to make a target list of antibodies?
    - Milestones must be met to complete payment
  - Should this effort focus primarily on a centralized mechanism for validating affinity reagents and storing this information?
    - Would a “seal of approval” and the opportunity to list the reagent in this “central database” be an incentive to develop these reagents?

# *Proposal Discussion Topics III*

- Distribution
  - Option 1: Centralized repository/distribution center
  - Option 2: Centralized database/producers handle their own distribution through standard commercial mechanisms
  - Both? Other?
  - IP considerations for distribution - limits?
  - If affinity reagents are contracted and paid for by NIH, who owns the IP rights to the reagents?

# *Proposal Discussion Topics IV*

- Validation
  - Which assays should be validated for?
    - Denatured protein
      - Western blot
      - ELISA
      - Immunohistochemistry
    - Native protein
      - Immunoprecipitation
      - Antibody arrays
      - Other...
  - How many affinity reagents needed per target?
  - Which criteria must be met to accept an antibody?
    - E.g., if an antibody is very good at only one of the above, is this ok?
  - Should validation be done at centralized facilities?
    - Or - is it ok for various centers to validate using the same criteria?